LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre Sells 8,000 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 8,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the sale, the chief executive officer now owns 2,079,128 shares in the company, valued at $156,558,338.40. The sale was disclosed in a document filed with the SEC, which is available through this link.

LeMaitre Vascular Price Performance

NASDAQ:LMAT opened at $75.00 on Thursday. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $76.24. The business’s 50-day moving average is $66.55 and its two-hundred day moving average is $59.34. The firm has a market capitalization of $1.68 billion, a PE ratio of 49.67, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. During the same quarter in the prior year, the business earned $0.27 EPS. LeMaitre Vascular’s quarterly revenue was up 13.6% compared to the same quarter last year. Equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s payout ratio is 42.38%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the company from $59.00 to $75.00 in a research note on Friday, April 26th. JMP Securities increased their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. KeyCorp assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They issued a “sector weight” rating on the stock. Finally, Barrington Research upped their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $73.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of LMAT. Mesirow Institutional Investment Management Inc. bought a new stake in shares of LeMaitre Vascular during the 4th quarter valued at about $8,837,000. Congress Asset Management Co. MA lifted its stake in LeMaitre Vascular by 36.3% in the third quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock valued at $27,696,000 after buying an additional 135,266 shares during the last quarter. Ranger Investment Management L.P. boosted its holdings in shares of LeMaitre Vascular by 15.8% during the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after acquiring an additional 122,601 shares during the period. Summit Creek Advisors LLC increased its holdings in shares of LeMaitre Vascular by 37.8% in the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock worth $12,970,000 after acquiring an additional 62,737 shares during the period. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of LeMaitre Vascular by 3.0% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier’s stock worth $104,470,000 after acquiring an additional 55,895 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.